Non-Tubercular Mycobacteria

Questions discussed in this category

Is there a role for dual antibiotic treatment with ethambutol and macrolide only, as opposed to three-drug antibiotic therapy, in the treatment of treatment-naive pulmonary MAC without cavitary disease?

3 Answers available

What is your preferred third antimicrobial agent for a patient with treatment-naive pulmonary MAC without cavitary disease and strict contraindications to utilization of rifampin or rifabutin?

3 Answers available

Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?

4 Answers available

Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?

2 Answers available

What are your top takeaways from ID Week 2024?

1 Answer available

What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?

1 Answer available

What is your approach to treatment of macrolide-sensitive localized bone/joint MAC disease?

1 Answer available

In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?

2 Answers available

Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?

1 Answer available

How long do you continue surveillance with imaging and sputum cultures in a patient with NTM with no indications for treatment?

3 Answers available

Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?

2 Answers available

Papers discussed in this category

Chest, 2023 Feb 17

Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease.

Related Topics